Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Approximately 50% of patients with aggressive non-Hodgkin's lymphomas (NHL) achieve a complete remission (CR) and cure with combination chemotherapy. The International Index is a useful clinical measure that predicts the patients' tolerance of therapy and likelihood of achieving CR, but it is not a direct measure of chemosensitivity. In this study we have investigated the predictive value of the tumor suppressor gene, p53, as a biological marker for response to treatment in the aggressive NHL. A retrospective study was carried out on 50 patients with aggressive NHL who were treated with CHOP chemotherapy. Treatment outcome was correlated with the expression of p53 in the lymphoma, as measured by routine immunohistochemistry using the monoclonal antibody Do-7. Forty percent of the lymphomas had >5% of the cells staining positively for p53 and this finding correlated significantly with response to treatment. Fifty percent of patients with p53 positive tumors achieved a CR versus 77% of patients with p53 negative tumors. In addition, the relapse rate and time to relapse were significantly different in the two groups. In the p53 positive group, 60% of patients relapsed in a median time of 6 months, whereas 26% of the p53 negative group relapsed with the time to relapse being >22 months. The overall survival of the p53 positive group (17 months) was significantly shorter than that of p53 negative group (>24 months). These results suggest that the immunohistochemical assessment of p53 is a simple and important prognostic measure for patients with aggressive NHL who are treated with CHOP chemotherapy.
 ...
PMID:Expression of p53 predicts treatment failure in aggressive non-Hodgkin's lymphomas. 963 83

The treatment of highly of 43 patients with highly malignant non-Hodgkin lymphomas were analysed and assessed. These patients were treated at the Department of Hematology, Pomeranian Medical Academy within 1981-1990. The process was advanced in 76% of and localization of the tumour outside lymph nodes was also seen in 79%. The results of treatment with CHOP regimen used during the first 5 years were compared with CBVPM-AVBP used in 1986-1990. CBVPM-AVBP regimen proved more 4 effective (55% of the complete remissions) than CHOP regimen (37.5% of the complete remission). Mean duration of the complete remission (survival free from the relapse) was 27.5 (1-88) months. Complete remissions were easier to achieve in patients with centroblastic lymphoma in higher percentage. These patients survived longer than those with other highly malignant lymphomas. The authors conclude that further intensification of chemotherapy in case of highly malignant non-Hodgkin lymphomas is justified.
 ...
PMID:[Results of treating patients with highly malignant non-Hodgkin's lymphomas; comparison of treatment efficacy with CHOP and CBVPM-AVBP]. 964 64

A case of renal malignant lymphoma is reported. A 74-year-old man was admitted to our hospital on September 8, 1995, complainning of right flank pain, abdominal mass, and anorexia for two months. Physical examination revealed an enlarged right axillary lymph node and abdominal mass of child's head size. Computerized tomography showed a tumor (11 x 7 cm) encompassing the right kidney parenchym, and enlarged paraaprtoc lymph nodes with invasion of the left iliac creat. Transcutaneous echo-guided needle biopsy revealed that the tumor was non-Hodgkin's malignant lymphoma, diffuse large cell type, positive for B cell marker. The patient was treated with full dose of CHOP regimen. However, adriamycin was replaced with pirarubicin and the dose of the other drugs were reduced for the subsequent 4 courses because of severe leukocytopenia, thrombocytopenia, hepatotoxicity, and alopecia after the first course of the treatment. The patient showed complete remission and discharged on March 12, 1996. He, after 17 months, has no signs of recurrence. We reviewed 43 Japanese cases previously reported as renal malignant lymphoma. It is increasing in Japan especially in elderly. The 2-year survival is 26.6%.
 ...
PMID:[Renal malignant lymphoma: report of a patient surviving 17 months without recurrence and review of 43 Japanese cases]. 964 94

The CHOP regimen (cyclophosphamide vincristine, adriamycin, prednisone) is considered since twenty years as the standard treatment of disseminated aggressive non-Hodgkin's lymphomas and cures approximately 30% of patients. More recently, intensive chemo(radio)therapy followed by rescue with bone marrow or blood hematopoietic stem cells has become the standard treatment of chemosensitive relapses of aggressive non-Hodgkin's lymphomas. Consequently, two questions with practical applications have arisen and are discussed in this review: Is it justified to increase the dose intensity of chemotherapy, using either single treatment intensification with stem-cell rescue, or sequential intensified chemotherapies, especially in cases with adverse prognostic factors? On the contrary, is a decrease in treatment intensity compared to CHOP chemotherapy, especially in elderly patients, harmful to the patient?
 ...
PMID:[Dose-effects and chemotherapy dose intensity of aggressive non-Hodgkin's lymphomas in the adult]. 975 11

Intermediate-grade lymphomas are defined by the Working Formulation to include four histologic subgroups: follicular large-cell, diffuse small-cleaved-cell, diffuse mixed small- and large-cell, and diffuse large cell (Groups D, E, F, and G, respectively). [1] These four histologic subtypes were found to have "intermediate" median and overall survival features based on outcome analysis of 1,153 patients with non-Hodgkin's lymphomas. Clinicians, however, have come to "expect" different criteria for intermediate-grade lymphomas. Those criteria include an aggressive growth rate, a high risk of fatality early in the disease course without treatment, and a potential for cure using CHOP chemotherapy (cyclophosphamide [Cytoxan, Neosar], doxorubicin [Adriamycin], vincristine [Oncovin], and prednisone). The expectations are summarized by overall survival graphs demonstrating an initial steep curve, followed by a discernible change in slope, and ending in a relatively flat line or plateau representing the proportion of patients cured. [2] That is, an intermediate-grade lymphoma should be an aggressive disease that is potentially curable with CHOP. In that respect, the Working Formulation is partly successful, but not by design.
 ...
PMID:Management of intermediate-grade lymphomas. 983 Jun 31

We summarize in this article the antitumor activity of newly developed drugs against non-Hodgkin's lymphoma. The Taxans (paclitaxel and docetaxel), complex polycyclic organic chemicals isolated from the yew tree, have a broad antitumor spectrum with impressive activity in solid tumors. In the SWOG Phase II study on relapsed non-Hodgkin's lymphomas, paclitaxel (Taxol), showed 30% CR and 14% PR. In the CALGB study on docetaxel, a 14.5% response rate (12.5% for low-grade lymphoma and 16.1% for intermediate-high grade lymphoma) was found. In the Japanese phase II study of docetaxel, the response rate was 29.4% for all patients (14.3% for low-grade lymphoma and 40.0% for intermediate-high grade lymphoma). Rituximab is a chimeric monoclonal antibody directed against the B-cell specific antigen CD20. A phase II trial was conducted with four weekly infusions of 375 mg/m2 in patients with relapsed low-grade or follicular lymphoma. The response rate was 46%. A clinical trial combining Rituximab with 6 cycles of CHOP chemotherapy in newly diagnosed patients has recently been completed. Early evaluation of this experience suggests that this combination resulted in a PR or CR in all patients. New purine nucleoside analogs (fludarabine, cladribine, pentostatin) are active against common and generally incurable low-grade lymphoproliferative disorders. These new drugs combined with other chemotherapeutic reagents are expected to overcome refractory or incurable non-Hodgkin's lymphoma.
 ...
PMID:[New antitumor drugs for non-Hodgkin's lymphoma]. 988 Oct 79

Hematologic tumors are commonly systemic on diagnosis, and chemotherapy is therefore the sole method by which to obtain a prolongation of survival or cure. Based upon results from a prospective randomized trial compared to a combination regimen consisting of daunorubicin and cytarabine, the first line chemotherapeutic regimen for acute myelogenous leukemia is considered to be a combination regimen consisting of idarubicin and cytarabine. The standard chemotherapeutic regimen for advanced Hodgkin's disease would seem to be an ABVD regimen, judging from results reported from a prospective randomized trial which compared MOPP, ABVD and MOPP-ABVD. The first generation combination CHOP is recognized as a standard regimen for advanced non-Hodgkin lymphoma due to results of a prospective randomized trial compared with intensive chemotherapeutic regimens.
 ...
PMID:[Hematologic tumors]. 1041 Jun 71

An 18-year-old female was introduced our hospital for facial swelling and subcutaneous tumor of anterior neck. Chest X-ray and CT films showed mediastinal mass with tracheo-bronchial stenosis. Incisional biopsy specimens of neck tumor revealed that the tumor was suggestive of malignant lymphoma. Because of progressive dyspnea after CHOP regimens the operation was performed and histopathological examinations revealed thymic Hodgkin's disease. After operation dyspnea was improved but dysphagia and hoarseness occurred. These symptoms were getting improved. She received 6 cycles of ABVD regimens and discharged after 5 months.
 ...
PMID:[A case of surgical treatment for thymic Hodgkin's disease with tracheo-bronchial stenosis]. 1045 72

We report a 27-year-old woman with a non-Hodgkin lymphoma in the central nervous system (CNS), showing monoparesis of the right upper extremity during treatment for the galactorrhea amenorrhea syndrome. The MRI demonstrated an infiltrative lesion with an obvious gadolinium-enhancement effect, extending from the pituitary stalk and hypothalamus through the 4th ventricle to the dorsal part of the medulla and upper cervical spinal cord. Because no tumors were detected in any other organ in either a physical examination or radiological investigations, including CT for the chest and abdomen, she was diagnosed as having primary CNS non-Hodgkin lymphoma (B cell origin) on the basis of an open brain biopsy. After the irradiation of the whole brain, followed by chemotherapy (methotrexate + CHOP), the infiltrative tumor disappeared on the MRI with a slight improvement for monoparesis of the right upper extremity. In this patient, primary CNS lymphoma might originate around the hypothalamus and infiltrate the medulla, inducing not only monoparesis of the right upper extremity but the galactorrhea amenorrhea syndrome.
 ...
PMID:[A case of non-Hodgkin lymphoma in the central nervous system, developing during treatment of galactorrhea amenorrhea syndrome]. 1068 43

We report a 71-year-old female patient with repeated vomitus, meteorism, epigastric pain and reflux for more than four month. She had a palpable mass in the upper abdomen and lost 7 kg of weight during the last four months. Chest X-ray showed two masses, 2 cm and 3 cm in diameter, in the left and right lower lung. A stenosing polypoid mucosal swelling in the antrum and the duodenal bulb. The pulmonal masses were biopsied under CT-guidance. Biopsy proved a high malignant B-cell non-Hodgkin's lymphoma of the stomach. The masses in the lung were identified as metastases of the gastrointestinal lymphoma. In conclusion on this tumor was an extranodal non-Hodgkin's lymphoma stadium BE IV according to Musshoff. A CHOP-chemotherapy was initiated. Restaging after three cycles of CHOP revealed a complete remission. Primary gastrointestinal non-Hodgkin's lymphomas are relatively rare neoplasms of the abdomen. Unusual and interesting in this case ist the metastatic pattern involving the lung periphery without local lymph node metastases.
 ...
PMID:[Pulmonary metastasis of extranodal high malignancy B-cell non-Hodgkin lymphoma of the bulbus duodeni and pylorus of the stomach]. 1072 Nov 74


<< Previous 1 2 3 4 5 6 7 8 9 10